Status:
COMPLETED
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Vaccines
Pneumococcal Conjugate Vaccine
Eligibility:
All Genders
42-98 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC)...
Eligibility Criteria
Inclusion
- Healthy 2-month-old infants (42 to 98 days)
- Available for the entire study period (14 months)
Exclusion
- Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis, polio, or Hib vaccines
- A previous anaphylactic reaction to any vaccine or vaccine-related component.
Key Trial Info
Start Date :
June 5 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2010
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT00688870
Start Date
June 5 2008
End Date
January 13 2010
Last Update
October 7 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100
2
Chang Gung Memorial Hospital - Linko
Taoyuan Hsien, Taiwan, 333